Regenxbio
RGNX
182 hedge funds and large institutions have $1.4B invested in Regenxbio in 2021 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 71 increasing their positions, 54 reducing their positions, and 17 closing their positions.
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
31% more repeat investments, than reductions
Existing positions increased: 71 | Existing positions reduced: 54
8% more capital invested
Capital invested by funds: $1.3B → $1.4B (+$100M)
6% more funds holding
Funds holding: 172 → 182 (+10)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.39% less ownership
Funds ownership: 78.79% → 78.4% (-0.39%)
81% less call options, than puts
Call options by funds: $5.36M | Put options by funds: $28.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$15.1M |
| 2 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$8.77M |
| 3 |
First Manhattan
New York
|
+$6.29M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.89M |
| 5 |
BlackRock
New York
|
+$5.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$10.8M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$10.3M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$8.04M |
| 4 |
D.E. Shaw & Co
New York
|
-$7.25M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$6.97M |
RGNX Hedge Fund Activity: Q3 2021 in Review
182 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q3 2021, worth a combined $1.4B — up 7.7% from $1.3B a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new RGNX positions and 17 closed out — a net gain of 11 holders — while 71 added to existing stakes and 54 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $15.1M. The largest seller was Sofinnova Investments, cutting an estimated $10.8M.
- 182 institutional investors held Regenxbio (RGNX) as of Q3 2021, up from 172 in Q2 2021.
- Funds reported $1.4B of Regenxbio stock for Q3 2021, up 7.7% quarter-over-quarter.
- 28 funds opened new Regenxbio positions in Q3 2021 and 17 closed out, a net change of +11 holders.
- The largest Regenxbio buyer in Q3 2021 was JP Morgan Chase, an estimated $15.1M added.
- The largest Regenxbio seller in Q3 2021 was Sofinnova Investments, an estimated $10.8M sold.
Based on aggregated 13F filings for Q3 2021.